Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v24.i5.20
pages 445-492

Optimizing Drug Delivery for Enhancing Therapeutic Efficacy of Recombinant Human Endostatin in Cancer Treatment

Fuguo Xu
Department of Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
Qingyong Ma
Department of Hepatobiliary Surgery, First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710061, Shaanxi, China
Huanchen Sha
Department of Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

ABSTRACT

Recombinant human endostatin (rhEndostatin) is uniquely able to target neovascular endothelial cells (ECs) and has the potential for antiangiogenetic and antitumor activities. In this review, we explore experimental approaches and clinical trials focusing on drug delivery of endostatin. Continued endostatin therapy can maintain tumors in a state of dormancy, and no signs of drug-induced resistance have been observed. Prolonged delivery of endostatin may be achieved by using pumps (mini-osmotic pumps) or cell encapsulation systems. The largest benefit from rhEndostatin is expected when drug delivery of rhEndostatin is begun as early as possible. Although endostatin has shown promise in controlling tumor neovasculature, a major problem in pharmacotherapy is the side effects of constant drug administration and the limited half-life of antiangiogenic proteins. Gene therapy offers the advantages of maximizing cost effectiveness and maintaining sustained levels of antiangiogenic factors, which may enhance antitumor efficacy. Therefore, we have investigated recent advances in gene delivery of endostatin for cancer treatment. In recent years, preclinical and clinical data have demonstrated the synergistic effects of rhEndostatin combined with other therapies on inhibiting growth of malignant tumors, with minimal toxicity. rhEndostatin has not been proven to prolong the survival rate of patients challenged with cancer when used as single therapy. Thus, we suggest that the combination of rhEndostatin with chemotherapy, radiotherapy, and biotherapy (i.e., fusion protein, molecular-targeted therapy on cancers, etc.) might provide an optimal strategy for cancer treatment.


Articles with similar content:

Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Krishna Patel, Maya Nair, Riyaz Basha, Sohail Siraj, Jamboor K. Vishwanatha, Chloe Smith
Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 3
Rohit R. Bhosale, Bannimath Gurupadayya, Devegowda Vishakante Gowda, Koganti Venkata Sairam, Riyaz Ali Mahafez Ali Osmani, Rudra Vaghela, Hosahalli Veerabhadrappa Gangadharappa, Parthasarathi Keshavarao Kulkarni
Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Phillip A. Abarca, Caitlin Marx, Jennifer L. Strunck, Catherine Neumann, Kevin Y. Kim, Brian Wolf, Robert M. Elashoff, Edward B. Garon, Danielle Nameth
Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Ali Sharif, Wafa Majeed, Bushra Akhtar, Muhammad Furqan Akhtar, Faqir Muhammad
Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 4
R. S. R. Murthy, Suresh P. Vyas, Manish K. Gupta, Sahil Aggarwal, Swati Gupta